Jim Cramer discussed trial data from Moderna's Covid-19 vaccine candidate, saying he wants to see information about insider stock sales before deciding how confident to be.
have faced criticism as Moderna has provided regular updates on its Covid-19 vaccine candidate, which sometimes have contained incomplete information. Cramer said that the company has been promotional and is releasing data that it does not need to.
Moderna shares popped following the release of the trial data on Tuesday night. The stock price rose more than 12% to roughly $84.50 per share on Wednesday morning. Bancel sold roughly 20,000 shares on July 10, at an average price of around $64 per share. Bancel's moves were part of a pre-determined plan for stock sales.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Big banks report mixed earnings results — Cramer and others on what to watch nowJPMorgan's and Wells Fargo's earnings reports illustrate the two sides of banking during the pandemic, market watchers say.
Read more »
Charts suggest the S&P 500 climb will stall out at the end of July, Jim Cramer warnsThe charts, as interpreted by the legendary Larry Williams, suggest the S&P 500 could climb another 5% in coming weeks before equities begin to retreat, the 'Mad Money' host said.
Read more »
Moderna stock surges after releasing promising coronavirus vaccine trial dataModerna's stock surged early Wednesday after the biotech company said its potential coronavirus vaccine generated a promising immune response in an early-stage human trial.
Read more »
Early data from Moderna's coronavirus vaccine sparks Wall Street hopesModerna Inc's shares rose 17% on Wednesday after a small-scale study showed its experimental COVID-19 vaccine produced high levels of virus-killing antibodies, bolstering hopes the shot could prove effective in later stages of testing.
Read more »
Moderna's Early Coronavirus Vaccine Results Show It Can Spur An Immune ResponseTwo doses of the vaccine triggered the production of antibodies in all 45 patients tested, though the results are still preliminary.
Read more »
Moderna Inc.MRNA | Complete Moderna Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Read more »